Enzo Biochem, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ENZ 4.68 0.00 (0.00%)
price chart
Enzo Biochem, Inc. v. Applera Corp. (Fed. Cir. 2010)
Enzo The '824, '767, '928, and '830 patents, which are owned by Plaintiffs-Appellants Enzo Biochem, Inc., Enzo Life Sciences, Inc., and Yale University ("Enzo"), are directed to various techniques for labeling and detecting nucleic acids. More ...
Enzo Biochem Inc. (ENZ) Jumps 9.27% on December 17
Enzo Biochem Inc. ($ENZ) was among the biggest gainers on the Russell 2000 for Wednesday December 17 as the stock popped 9.27% to $4.48, representing a gain of $0.38 per share.
Enzo Biochem Inc. (ENZ) Drops 6.89% on November 20
Enzo Biochem Inc. (ENZ) was one of the Russell 2000's biggest losers for November 20 as the stock slid 6.89% to $4.19, a loss of $0.31 per share.
Related articles »  
Enzo Biochem Inc. (ENZ) Jumps 12.44% on December 17
Enzo Biochem Inc. ($ENZ) was among the biggest gainers on the Russell 2000 for Wednesday December 17 as the stock popped 12.44% to $4.61, representing a gain of $0.51 per share.
Related articles »  
Enzo Biochem Reports Strong Fiscal First Quarter Results
To comply with Regulation G promulgated pursuant to the Sarbanes-Oxley Act, Enzo Biochem attached to this news release and will post to the Company's investor relations web site (www.
Enzo Biochem Reports Higher Q1 Net Loss  RTT News
Enzo Biochem reports 1Q loss  CNBC
Related articles »  
Enzo Biochem Announces Appointment of James M. O'Brien as Senior VP ...
Jim has held leadership positions in the areas of planning and strategic development, financial analysis, SEC reporting and internal controls for both large and small multi-national public companies,� said Barry Weiner, President of Enzo Biochem, Inc ...
Enzo Biochem Unit Partners with Innate Pharma SA to Validate Key System for ...  MarketWatch
Healthcare Stocks Little Changed; Enzo Biochem, Innate Pharma Partnering on ...  NASDAQ
Related articles »  
Enzo Biochem Reports Strong Fiscal Fourth Quarter Results
NEW YORK, Oct 09, 2014 (BUSINESS WIRE) -- Enzo Biochem Inc. ENZ, +0.00% today reported results for the fourth quarter and fiscal year ended July 31, 2014, with continued solid year-end gains posted by both Life Sciences and Clinical Labs.
Related articles »  
Enzo Biochem (ENZ) in Focus: Stock Moves 6.9% Higher
Enzo Biochem Inc. (ENZ) was a big mover last session with its shares rising nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Enzo Biochem (ENZ) in Focus: Stock Moves 6.9% Higher - Tale of the Tape  Nasdaq
Related articles »  
Could Enzo Biochem's Intellectual Property Lawsuits Be Worth Billions?
Enzo Biochem, Inc. (NYSE:ENZ) is an integrated life sciences and biotechnology company divided into three segments: Enzo Clinical Labs, Enzo Life Sciences, and Enzo Therapeutics.
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the ...
What Falling Estimates amp; Price Mean for Enzo Biochem (ENZ)  Zacks.com
Related articles »